中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
1期
30-32
,共3页
心绞痛,不稳定型%C反应蛋白质%白细胞介素6%阿托伐他汀
心絞痛,不穩定型%C反應蛋白質%白細胞介素6%阿託伐他汀
심교통,불은정형%C반응단백질%백세포개소6%아탁벌타정
Angina pectoris,unstable%C-reactive protein%Interleukin-6%Atorvastatin
目的 探讨阿托伐他汀对不稳定型心绞痛(UAP)患者介入术后高敏C反应蛋白(hs-CRP)及白细胞介素6(IL-6)的影响.方法 选择80例UAP患者,均行经皮冠状动脉介入治疗(PCI),术后按照随机数字表法分为A组和B组,每组40例.A组患者在常规心内科治疗措施基础上给予阿托伐他汀20 mg治疗；B组在常规心内科治疗措施基础上给予阿托伐他汀40 mg治疗.分别于术前、术后24 h、术后3周抽血检测患者血清hs-CRP及IL-6水平,并进行比较.结果 术前A组和B组患者血清hs-CRP及IL-6水平比较差异无统计学意义[(5.6±1.2) mg/L比(5.6±1.1)mg/L和(211.9±21.2) ng/L比(209.6±19.9) ng/L,P＞ 0.05]；术后24hA组和B组患者血清hs-CRP及IL-6水平均较术前显著增高,差异有统计学意义(P＜0.05),但A组和B组比较差异无统计学意义[(8.1±1.1) mg/L比(8.5±1.2) mg/L和(311.1±20.9) ng/L比(313.3±18.5) ng/L,P＞0.05]；术后3周A组和B组患者血清hs-CRP及IL-6水平均较术前显著下降,差异有统计学意义(P＜0.05),A组和B组比较差异亦有统计学意义[(3.1±1.1) mg/L比(1.9±0.8) mg/L和(163.3±18.5) ng/L比(123.3±19.5) ng/L,P＜ 0.05],术后A组和B组患者均未出现明显的不良反应,肝功能均未见明显异常.结论 行PCI的UAP患者术后给予阿托伐他汀治疗可以明显降低患者血清hs-CRP和IL-6水平,且40 mg较20 mg治疗效果更明显,值得临床推广应用.
目的 探討阿託伐他汀對不穩定型心絞痛(UAP)患者介入術後高敏C反應蛋白(hs-CRP)及白細胞介素6(IL-6)的影響.方法 選擇80例UAP患者,均行經皮冠狀動脈介入治療(PCI),術後按照隨機數字錶法分為A組和B組,每組40例.A組患者在常規心內科治療措施基礎上給予阿託伐他汀20 mg治療；B組在常規心內科治療措施基礎上給予阿託伐他汀40 mg治療.分彆于術前、術後24 h、術後3週抽血檢測患者血清hs-CRP及IL-6水平,併進行比較.結果 術前A組和B組患者血清hs-CRP及IL-6水平比較差異無統計學意義[(5.6±1.2) mg/L比(5.6±1.1)mg/L和(211.9±21.2) ng/L比(209.6±19.9) ng/L,P＞ 0.05]；術後24hA組和B組患者血清hs-CRP及IL-6水平均較術前顯著增高,差異有統計學意義(P＜0.05),但A組和B組比較差異無統計學意義[(8.1±1.1) mg/L比(8.5±1.2) mg/L和(311.1±20.9) ng/L比(313.3±18.5) ng/L,P＞0.05]；術後3週A組和B組患者血清hs-CRP及IL-6水平均較術前顯著下降,差異有統計學意義(P＜0.05),A組和B組比較差異亦有統計學意義[(3.1±1.1) mg/L比(1.9±0.8) mg/L和(163.3±18.5) ng/L比(123.3±19.5) ng/L,P＜ 0.05],術後A組和B組患者均未齣現明顯的不良反應,肝功能均未見明顯異常.結論 行PCI的UAP患者術後給予阿託伐他汀治療可以明顯降低患者血清hs-CRP和IL-6水平,且40 mg較20 mg治療效果更明顯,值得臨床推廣應用.
목적 탐토아탁벌타정대불은정형심교통(UAP)환자개입술후고민C반응단백(hs-CRP)급백세포개소6(IL-6)적영향.방법 선택80례UAP환자,균행경피관상동맥개입치료(PCI),술후안조수궤수자표법분위A조화B조,매조40례.A조환자재상규심내과치료조시기출상급여아탁벌타정20 mg치료；B조재상규심내과치료조시기출상급여아탁벌타정40 mg치료.분별우술전、술후24 h、술후3주추혈검측환자혈청hs-CRP급IL-6수평,병진행비교.결과 술전A조화B조환자혈청hs-CRP급IL-6수평비교차이무통계학의의[(5.6±1.2) mg/L비(5.6±1.1)mg/L화(211.9±21.2) ng/L비(209.6±19.9) ng/L,P＞ 0.05]；술후24hA조화B조환자혈청hs-CRP급IL-6수평균교술전현저증고,차이유통계학의의(P＜0.05),단A조화B조비교차이무통계학의의[(8.1±1.1) mg/L비(8.5±1.2) mg/L화(311.1±20.9) ng/L비(313.3±18.5) ng/L,P＞0.05]；술후3주A조화B조환자혈청hs-CRP급IL-6수평균교술전현저하강,차이유통계학의의(P＜0.05),A조화B조비교차이역유통계학의의[(3.1±1.1) mg/L비(1.9±0.8) mg/L화(163.3±18.5) ng/L비(123.3±19.5) ng/L,P＜ 0.05],술후A조화B조환자균미출현명현적불량반응,간공능균미견명현이상.결론 행PCI적UAP환자술후급여아탁벌타정치료가이명현강저환자혈청hs-CRP화IL-6수평,차40 mg교20 mg치료효과경명현,치득림상추엄응용.
Objective To explore the effect of atorvastatin on high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) in unstable angina pectoris (UAP) patients after intervention.Methods Eighty cases with UAP who underwent percutaneous coronary intervention (PCI) were divided into group A and group B by random digits table method with 40 cases each after PCI.The patients in group A were given regular heart treatment and atorvastatin 20 mg treatment.The patients in group B were given regular heart treatment and atorvastatin 40 mg treatment.The serum hs-CRP and IL-6 was determined before treatment and 24 h,3 weeks after treatment and compared between two groups.Results There was no significant difference in the serum hs-CRP and IL-6 before treatment between group A and group B [(5.6 ± 1.2) mg/L vs.(5.6 ± 1.1) mg/L and (211.9 ± 21.2) ng/L vs.(209.6 ± 19.9) ng/L,P ＞ 0.05].The serum hs-CRP and IL-6 24 h after treatment in group A and group B were increased compared with that before treatment,and there was significant difference(P ＜ 0.05),but there was no significant difference between group A and group B[(8.1 ± 1.1) mg/L vs.(8.5 ± 1.2) mg/L and (311.1 ± 20.9) ng/L vs.(313.3 ± 18.5) ng/L,P＞ 0.05].The serum hs-CRP and IL-6 3 weeks after treatment in group A and group B were decreased compared with that before treatment,there were significant difference (P ＜ 0.05),and there were significant difference between group A and group B [(3.1 ± 1.1) mg/L vs.(1.9 ±0.8) mg/L and (163.3± 18.5) ng/L vs.(123.3± 19.5)ng/L,P ＜ 0.05].No obvious adverse reaction was observed in two groups after treatment and liver function was not seen obvious anomaly.Conclusions Atorvastatin treatment in UAP patients after PCI can significantly reduce the serum hs-CRP and IL-6,and the 40 mg treatment is better than the 20 mg treatment.It is worth of clinical application.
